A new multicentre trial found that a single dose of esketamine, a fast-acting antidepressant derived from ketamine, given around childbirth helped prevent postpartum depression in first-time mothers. It published alongside a critical comment and the authors’ reply defending the design, a signal that the findings drew immediate scrutiny. The desk has deprioritized esketamine-postpartum efficacy headlines, which have piled up inconclusively for years without settling much. This one is worth covering not for the result but for the argument: the published objections are the two methodological problems that recur across this entire class of drug.
The trial
Across three academic hospitals, investigators enrolled first-time mothers scheduled for elective caesarean delivery. All were screened as not depressed before birth, using a low threshold on the Edinburgh Postnatal Depression Scale. Patients were randomized to either a single sub-anesthetic dose of esketamine, followed by esketamine as an add-on to 24-hour patient-controlled intravenous analgesia, or to saline. The primary outcome was the incidence of postpartum depression over the following months, and the authors concluded that esketamine was relatively safe and reduced it. This is a prevention study, not a treatment one. It asks whether a one-time perioperative drug can keep relatively low-risk women from developing postpartum depression in the first place.
The first objection: the blind
Esketamine produces noticeable acute effects, such as dizziness, dissociation, and perceptual changes, that a saline placebo does not. When the active arm reliably experiences sensations the placebo arm never feels, patients, and sometimes the people assessing them, can infer which group they are in. That knowledge can contaminate a subjective, self-reported outcome like a depression-screening score. This is functional unblinding. It is the same problem the desk has tracked through the psychedelic trials, the accelerated-TMS sham question, and the lysergide program, which deliberately built a low-dose active control to fight it. A postpartum prevention trial that pairs a perceptible active drug with a questionnaire endpoint is squarely exposed to it. The published critique pressed on exactly this point, citing a markedly higher rate of transient neuropsychiatric adverse events in the esketamine arm. If the women who got the drug could tell, the apparent benefit may partly reflect expectancy instead of pharmacology.
The second objection: the confound
The esketamine was not given in isolation. It was delivered in part as an adjunct to patient-controlled analgesia, and esketamine is itself an analgesic. Better postoperative pain control can lift mood and lower depression-screening scores on its own. That means the trial’s apparent preventive effect is entangled with its pain-relieving effect. The exchange between critic and authors turns largely on this: whether the reduction in postpartum depression reflects a real antidepressant action or a downstream consequence of short-term opioid-sparing analgesia. Disentangling a mood mechanism from a pain mechanism is difficult when the same drug does both and is dosed through the same pump, and this design does not cleanly separate them.
The Right Way to Read This Trial
The esketamine-for-postpartum literature is large, mixed, and dominated by perioperative trials whose results contradict one another. Meta-analyses lean positive, individual randomized trials disagree, and effects often look transient. Adding one more efficacy headline to that pile tells a reader very little. What the published exchange does is model the correct way to read these studies. This is a dramatic prevention claim, made in women who were not depressed to begin with, measured by a subjective screen. It comes from a drug whose side effects can break the blind and whose analgesic action confounds the endpoint. Both problems have to stay in view when judging the result. The comment and reply are the field doing that work in real time, which is more useful to follow than any single point estimate.
What This Exchange Doesn’t Settle
This is not evidence that esketamine fails to prevent postpartum depression. The literature is contested, and several trials are positive. The critique is a single published comment, and the authors defended their design in their reply; the desk is not adjudicating who is right. And prevention in low-risk women is a distinct question from treating diagnosed postpartum depression or major depression, where the evidence base and the stakes differ. The point here is the methodological terrain, not a verdict on the drug.
What This Debate Reveals About the Whole Drug Class
The desk’s standing read on the esketamine-postpartum cluster has been that the efficacy headlines outrun the evidence. A trial that publishes with its own rebuttal attached is, in effect, the cluster conceding the point. The two objections, a blind the drug may have broken and a benefit braided into pain relief, are not unique to obstetric care. They are the recurring obstacles to believing any subjective endpoint produced by a drug the patient can feel. The thing to watch is whether the next wave of trials in this space designs around them, with active controls and analgesia-matched comparison arms, or keeps generating results that need a comment printed next to them.